Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?

Internal Medicine Journal

Volumn 39, Issue 8, 2009, Pages 527-531

  Soulsby, N ^a,b   Bell, S ^c   Greville, H ^d   Doecke, C ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Pharmacy Department   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Aminoglycosides; Cystic fibrosis; Monitoring; Tobramycin; Toxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; GENTAMICIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; BODY WEIGHT; BRONCHIECTASIS; CHILD; CYSTIC FIBROSIS; DRUG MONITORING; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; NEPHROTOXICITY; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; AUSTRALIA; CHILD; CYSTIC FIBROSIS; DRUG MONITORING; HEARING LOSS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; QUESTIONNAIRES; YOUNG ADULT;

EID: 69549138169     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01787.x     Document Type: Article

References (24)

1. Massie RJ, Delatycki MB, Bankier A. Screening couples for cystic fibrosis carrier status: why are we waiting? Med J Aust 2005 183 : 501 502.
2. Dobbin CJ, Bye PT. Adults with cystic fibrosis: meeting the challenge!. Intern Med J 2003 33 : 593 597.
3. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995 39 : 605 609.
4. Phillips JA, Bell SC. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Intern Med J 2001 31 : 23 6.
5. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005 39 : 15 20.
6. Glass S, Plant ND, Spencer DA. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis. J Cyst Fibros 2005 4 : 221 225.
7. Al-Aloul M, Jackson M, Bell G, Ledson M, Walshaw M. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros 2007 6 : 41 7.
8. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999 36 : 89 98.
9. Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Crit Care 2001 7 : 401 408.
10. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 2000 44 : 809 813.
11. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006 58 : 822 829.
12. Smyth A, Touw D, Tan KH, Bertenshaw C, Stableforth S. Tobramycin dosing in cystic fibrosis. Lancet 2005 365 : 1767 1768.
13. Tan KH, Hyman-Taylor P, Mulheran M, Knox A, Smyth A. Once-daily tobramycin monotherapy in cystic fibrosis. Pediatr Pulmonol 2002 33 : 406, author reply 407.
14. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007 6 : 327 333.
15. Vandenbussche HL, Klepser ME. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs? Lancet 2005 365 : 547 548.
16. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002 19 : 303 309.
17. UK Cystic Fibrosis Trust Antibiotic Group. Addendum for Antibiotic Treatment for Cystic Fibrosis, 2nd edn. Cystic Fibrosis trust 2002, 2004 [cited 2008 Jan]. Available from: URL: http://www.cftrust.org.uk/aboutcf/publications/ consensusdoc/AddendumAntibiotics-Jan-2004.pdf
18. Monitoring and dosing of aminoglycosides. In : Johnstone J, ed. Antibiotic Version 13 Australia. Melbourne : Therapeutic Guidelines Ltd 2006 Appendix 2.4.
19. Campbell D, Thomson A, Stack B. Population pharmacokinetics of aminoglycosides antibiotics in patients with cystic fibrosis. Ther Drug Monit 1999 21 : 281 288.
20. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in patients with cystic fibrosis. Pharm World Sci 1998 20 : 149 160.
21. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996 312 : 338 344.
22. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005 365 : 573 578.
23. Bertenshaw C, Watson AR, Lewis S, Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007 62 : 541 545.
24. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000 [Published erratum appears in Thorax 1992; 47: 139 Thorax 1991 46 : 881 885.